| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
PACS
PACS Group Inc
|
Sep 04, 2026 | BUY |
Strong Buy
+13.4% avg upside
9 analysts
|
$58.00
36.38% Upside
|
+0.0% | · |
|
UHS
Universal Health
|
Sep 03, 2026 | HOLD |
Buy
+15.8% avg upside
22 analysts
|
$200.00
17.91% Upside
|
+1.6% | · |
|
THC
Tenet Healthcare
|
Sep 01, 2026 | BUY |
Strong Buy
-9.3% avg upside
27 analysts
|
$315.00
18.92% Upside
|
-0.3% | · |
|
HCA
HCA Healthcare
|
Aug 24, 2026 | HOLD |
Buy
+0.3% avg upside
36 analysts
|
$425.00
4.87% Upside
|
-6.3% | · |
|
LMRI
Lumexa Imaging Holdings, Inc.
|
Aug 10, 2026 | BUY |
Strong Buy
+61.6% avg upside
8 analysts
|
$18.00
47.83% Upside
|
+3.8% | · |
|
GMRS
GMR Solutions, Inc. Class A
|
Aug 10, 2026 | BUY |
Strong Buy
+38.5% avg upside
9 analysts
|
$15.00
11.47% Upside
|
+6.4% | · |
|
CON
Concentra Group Holdings Parent, Inc.
|
May 22, 2026 | BUY |
Strong Buy
+12.9% avg upside
12 analysts
|
$34.00
1.34% Downside
|
+36.5% | · |
|
USPH
US Physical Therapy
|
May 18, 2026 | BUY |
Strong Buy
+16.2% avg upside
12 analysts
|
$90.00
13.44% Upside
|
+23.6% | · |
|
AVAH
Aveanna Healthcare Holdings
|
Mar 27, 2026 | HOLD |
Buy
-22.0% avg upside
18 analysts
|
$8.00
41.19% Downside
|
+115.9% | · |
|
SGRY
Surgery Partners
|
Mar 27, 2026 | HOLD |
Strong Buy
+66.3% avg upside
18 analysts
|
$14.00
1.89% Downside
|
+25.0% | · |
|
INNV
InnovAge Holding
|
Feb 23, 2026 | SELL |
Hold
-26.1% avg upside
12 analysts
|
$7.00
34.85% Downside
|
-20.7% | · |
|
ARDT
Ardent Health Partners, Inc.
|
Nov 24, 2025 | HOLD |
Buy
+27.8% avg upside
16 analysts
|
$12.00
10.04% Upside
|
+22.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.